These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552. Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833 [TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo. Darius H; Smith JB; Lefer AM J Pharmacol Exp Ther; 1985 Nov; 235(2):274-81. PubMed ID: 2997428 [TBL] [Abstract][Full Text] [Related]
10. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161 [TBL] [Abstract][Full Text] [Related]
11. The hepoxilin analog PBT-3 inhibits heparin-activated platelet aggregation evoked by ADP. Reynaud D; Hinek A; Pace-Asciak CR FEBS Lett; 2002 Mar; 515(1-3):58-60. PubMed ID: 11943194 [TBL] [Abstract][Full Text] [Related]
12. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel. Heinisch G; Holzer W; Kunz F; Langer T; Lukavsky P; Pechlaner C; Weissenberger H J Med Chem; 1996 Sep; 39(20):4058-64. PubMed ID: 8831771 [TBL] [Abstract][Full Text] [Related]
13. Evidence for a role for phospholipase C, but not phospholipase A2, in platelet activation in response to low concentrations of collagen. Lockhart LK; Pampolina C; Nickolaychuk BR; McNicol A Thromb Haemost; 2001 May; 85(5):882-9. PubMed ID: 11372683 [TBL] [Abstract][Full Text] [Related]
14. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619. Johnson GJ; Leis LA; Francis GS Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526 [TBL] [Abstract][Full Text] [Related]
15. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953 [TBL] [Abstract][Full Text] [Related]
16. Laser-induced stimulation of thromboxane B2 synthesis in human blood platelets: role of superoxide radicals. Arora RR; Mueller HS; Sinha AK Am Heart J; 1993 Feb; 125(2 Pt 1):357-62. PubMed ID: 8381256 [TBL] [Abstract][Full Text] [Related]
17. Nifedipine reduces thromboxane A2 production by platelets without changing aggregation in hypertensive pregnancy. Manninen A Pharmacol Toxicol; 1996 Jun; 78(6):387-91. PubMed ID: 8829198 [TBL] [Abstract][Full Text] [Related]
18. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. Mikhailidis DP; Barradas MA; Maris A; Jeremy JY; Dandona P J Clin Pathol; 1985 Oct; 38(10):1166-71. PubMed ID: 3902901 [TBL] [Abstract][Full Text] [Related]
19. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects. Morio H; Hirai A; Terano T; Tamura Y; Yoshida S Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052 [TBL] [Abstract][Full Text] [Related]
20. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist. Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]